Gaucher's ERT row heats up as Shire rejects Genzyme suit
This article was originally published in Scrip
Executive Summary
Genzyme says it will "aggressively" pursue its complaint that its rival Shire allegedly put out "misleading statements" in a press release about a head to head trial looking at the firms' competing enzyme replacement therapies for Gaucher's disease. Genzyme's comments came after Shire filed for the dismissal of the suit in a Massachusetts court because, as Shire told Scrip, "it was concerned that Genzyme was seeking to stifle both the company's legitimate communications to investors as well genuine discussion and exchange of scientific data."
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.